0.8601
price down icon13.99%   -0.1399
 
loading
Schlusskurs vom Vortag:
$1.00
Offen:
$1.03
24-Stunden-Volumen:
431.57K
Relative Volume:
2.52
Marktkapitalisierung:
$11.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.91M
KGV:
-0.5952
EPS:
-1.445
Netto-Cashflow:
$-15.07M
1W Leistung:
-29.50%
1M Leistung:
-55.44%
6M Leistung:
-46.91%
1J Leistung:
-78.60%
1-Tages-Spanne:
Value
$0.8375
$1.04
1-Wochen-Bereich:
Value
$0.8375
$1.2705
52-Wochen-Spanne:
Value
$0.8375
$4.7034

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Firmenname
Lantern Pharma Inc
Name
Telefon
972-277-1136
Name
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Mitarbeiter
16
Name
Twitter
@lanternpharma
Name
Nächster Verdiensttermin
2026-11-11
Name
Neueste SEC-Einreichungen
Name
LTRN's Discussions on Twitter

Compare LTRN vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
LTRN icon
LTRN
Lantern Pharma Inc
0.8601 15.60M 0 -15.91M -15.07M -1.445
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
504.73 133.37B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
190.01 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
735.20 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
919.21 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
206.64 43.93B 742.00K -1.37B -1.07B -7.0731

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-10-07 Eingeleitet H.C. Wainwright Buy

Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten

pulisher
Oct 01, 2026

Lantern Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Oct 01, 2026
pulisher
Oct 01, 2026

Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering - The Globe and Mail

Oct 01, 2026
pulisher
Oct 01, 2026

Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance UK

Oct 01, 2026
pulisher
Oct 01, 2026

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering - biospace.com

Oct 01, 2026
pulisher
Sep 30, 2026

Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com South Africa

Sep 30, 2026
pulisher
Sep 30, 2026

Lantern Pharma Raises $4.0 Million in Registered Direct; Issues Warrants, Engages Rodman & Renshaw - TradingView

Sep 30, 2026
pulisher
Sep 30, 2026

Form 424B5 Lantern Pharma Inc For: 30 September - Investing.com India

Sep 30, 2026
pulisher
Sep 29, 2026

Lantern Pharma Inc. (LTRN) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 29, 2026
pulisher
Sep 29, 2026

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering - biospace.com

Sep 29, 2026
pulisher
Sep 29, 2026

Lantern Pharma raises $4M in registered direct offering - Investing.com

Sep 29, 2026
pulisher
Sep 29, 2026

Lantern Pharma announces up to $8M registered direct offering - TradingView

Sep 29, 2026
pulisher
Sep 24, 2026

Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com Nigeria

Sep 24, 2026
pulisher
Sep 24, 2026

Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform - TradingView

Sep 24, 2026
pulisher
Sep 24, 2026

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic DevelopmentSlideshow (NASDAQ:LTRN) 2026-09-24 - Seeking Alpha

Sep 24, 2026
pulisher
Sep 23, 2026

Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent - The Globe and Mail

Sep 23, 2026
pulisher
Sep 23, 2026

LTRN: Open Medicine AI expands its platform, targeting new diseases and broader adoption in drug development - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET - BioSpace

Sep 23, 2026
pulisher
Sep 23, 2026

Lantern Pharma Showcases Open-Medicine AI Growth Strategy - TipRanks

Sep 23, 2026
pulisher
Sep 23, 2026

Form 8K Lantern Pharma Inc For: 23 September By Investing.com - Investing.com Nigeria

Sep 23, 2026
pulisher
Sep 23, 2026

Lantern Pharma to present Open-Medicine AI roadmap, demo, commercial model in live webinar - TradingView

Sep 23, 2026
pulisher
Sep 22, 2026

Lantern Pharma receives patent allowance for LP-284 cancer drug By Investing.com - Investing.com South Africa

Sep 22, 2026
pulisher
Sep 22, 2026

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas - biospace.com

Sep 22, 2026
pulisher
Sep 22, 2026

Lantern Pharma (LTRN) Secures Patent Allowance for Blood Cancer Treatment, Faces Valuation Challenges - GuruFocus

Sep 22, 2026
pulisher
Sep 22, 2026

Lantern Pharma secures USPTO notice of allowance for LP-284 patent - TipRanks

Sep 22, 2026
pulisher
Sep 22, 2026

Lantern Pharma receives patent allowance for LP-284 cancer drug - Investing.com

Sep 22, 2026
pulisher
Sep 20, 2026

Lantern Pharma to host webinar on Open-Medicine AI - TipRanks

Sep 20, 2026
pulisher
Sep 19, 2026

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Eagle-Tribune

Sep 19, 2026
pulisher
Sep 19, 2026

Lantern Pharma Inc (NASDAQ: LTRN) Share Price, LTRN Stock News, LTRN Share Price & Updates - kalkine.ca

Sep 19, 2026
pulisher
Sep 18, 2026

Lantern Pharma Q2 2026 Earnings Call: Complete Transcript - Benzinga

Sep 18, 2026
pulisher
Sep 18, 2026

Lantern Pharma to Present Open-Medicine AI, a Multi-Agentic Platform for End-to-End Therapeutic Development, Business Model, Roadmap, and Value Proposition on September 23 - marketscreener.com

Sep 18, 2026
pulisher
Sep 18, 2026

LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill

Sep 18, 2026
pulisher
Sep 17, 2026

Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap - Barchart.com

Sep 17, 2026
pulisher
Sep 17, 2026

Lantern Pharma (LTRN) to Host Webinar Highlighting AI-Driven The - GuruFocus

Sep 17, 2026
pulisher
Sep 17, 2026

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 - Yahoo Finance

Sep 17, 2026
pulisher
Sep 12, 2026

Lantern Pharma Share PriceLTRN, RNS News, Articles, Quotes, & Charts (NASDAQ:LTRN) - Proactive financial news

Sep 12, 2026
pulisher
Sep 09, 2026

Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits

Sep 09, 2026
pulisher
Sep 05, 2026

New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - guardonline.com

Sep 05, 2026
pulisher
Aug 29, 2026

Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe

Aug 29, 2026
pulisher
Aug 24, 2026

Lantern Pharma Earnings Call: AI Spinout, Trial Momentum - TipRanks

Aug 24, 2026
pulisher
Aug 21, 2026

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com

Aug 21, 2026
pulisher
Aug 21, 2026

Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm

Aug 21, 2026
pulisher
Aug 19, 2026

Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus

Aug 19, 2026
pulisher
Aug 19, 2026

Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... - Yahoo Finance

Aug 19, 2026
pulisher
Aug 19, 2026

Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Aug 19, 2026
pulisher
Aug 18, 2026

Lantern Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026
pulisher
Aug 17, 2026

Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha

Aug 17, 2026
pulisher
Aug 17, 2026

Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn

Aug 17, 2026
pulisher
Aug 16, 2026

Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus

Aug 16, 2026
pulisher
Aug 15, 2026

Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn

Aug 15, 2026

Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lantern Pharma Inc-Aktie (LTRN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
KEYSER D JEFFREY
Director
May 12 '26
Buy
2.06
48,544
100,001
94,303
$96.90
price up icon 0.05%
$57.16
price down icon 0.82%
$35.72
price up icon 0.62%
$219.72
price down icon 4.96%
ONC ONC
$358.07
price down icon 0.20%
$206.64
price up icon 0.36%
Kapitalisierung:     |  Volumen (24h):